Metabolomic and inflammatory signatures in congenital hypothyroidism: a longitudinal analysis of levothyroxine response - Top-Institutions - MDSpire

Metabolomic and inflammatory signatures in congenital hypothyroidism: a longitudinal analysis of levothyroxine response

  • By

  • Marcela Vela-Amieva

  • Isabel Ibarra-González

  • Raúl Calzada León

  • María de la Luz Ruiz-Reyes

  • María Eugenia Constantini

  • Sara Guillén-López

  • Lizbeth López-Mejía

  • Michelle Citlalli Luna-Nequiz

  • Rosa Itzel Carrillo-Nieto

  • Cynthia Fernández-Lainez

  • July 1, 2026

  • 0 min

Share

Top Institutions in Endocrinology

Brief introduction explaining scope and methodology.

  • #1

    Biochemistry and Endocrinology Laboratory of the National Institute of Pediatrics
    Biochemistry and Endocrinology Laboratory of the National Institute of Pediatrics

    Mexico City, Mexico

    Key Differentiators

    • Endocrinology

  • #2

    Referral Regional Center for CH of Pisa
    Referral Regional Center for CH of Pisa

    Pisa, Italy

    Key Differentiators

    • Endocrinology

  • #3

    Pediatric Endocrine Units
    Pediatric Endocrine Units

    Israel, Israel

    Key Differentiators

    • Endocrinology

  • #4

    The Environmental Determinants of Diabetes in the Young (TEDDY) study
    The Environmental Determinants of Diabetes in the Young (TEDDY) study

    Various, USA

    Key Differentiators

    • Endocrinology

  • #5

    Controlled Antenatal Thyroid Screening Study III
    Controlled Antenatal Thyroid Screening Study III

    Various, USA

    Key Differentiators

    • Endocrinology

Original Source(s)

Metabolomic and inflammatory signatures in congenital hypothyroidism: a longitudinal analysis of levothyroxine response

  • by Marcela Vela-Amieva, Isabel Ibarra-González, Raúl Calzada León, María de la Luz Ruiz-Reyes, María Eugenia Constantini, Sara Guillén-López, Lizbeth López-Mejía, Michelle Citlalli Luna-Nequiz, Rosa Itzel Carrillo-Nieto, Cynthia Fernández-Lainez

  • July 1, 2026

Related Content

FDA Expands OTC CGM Access to Children

The device was previously cleared for adults aged 18 years and older in March 2024.

FDA Monthly Preview: Key July Decisions to Watch

Several FDA decisions across multiple specialties are expected this month.

Disease site as an independent predictor of survival in radioiodine-refractory thyroid cancer